High Efficiency Diffusion Molecular Retention Tumor Targeting

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Guo, Yanyan ^a   Yuan, Hushan ^a   Cho, Hoonsung ^a   Kuruppu, Darshini ^a   Jokivarsi, Kimmo ^a,b   Agarwal, Aayush ^a   Shah, Khalid ^a   Josephson, Lee ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINYLALANYLASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; FLUOROCHROME; INDIUM 111; INTEGRIN; MACROGOL; TETRAXETAN; TRIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PARAMETERS; BREAST CARCINOMA; CANCER MODEL; CONTROLLED STUDY; DIFFUSION; DIFFUSION MOLECULAR RETENTION TUMOR TARGETING; FEMALE; FLUORESCENCE ANALYSIS; INTERSTITIAL DIFFUSION; INTERSTITIUM; MOLECULAR PROBE; MOLECULAR RECOGNITION; MOLECULARLY TARGETED THERAPY; MOUSE; NEAR INFRARED FLUORESCENCE; NONHUMAN; PROTEIN INTERACTION; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SURFACE FLUORESCENCE; TISSUE SPECIFICITY; VASCULAR UPTAKE;

ANIMALS; CELL LINE, TUMOR; DIFFUSION; FEMALE; FLUORESCENT DYES; GENES, REPORTER; HUMANS; INJECTIONS; INTEGRINS; MICE; MOLECULAR IMAGING; NEOPLASMS; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874889361     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058290     Document Type: Article

References (52)

1. Guo Y, Yuan H, Rice WL, Kumar AT, Goergen CJ, et al. (2012) The PEG-Fluorochrome Shielding Approach for Targeted Probe Design. J Am Chem Soc. 134(47): 19338-41.
2. Jain RK, (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9: 253-266.
3. Thurber GM, Schmidt MM, Wittrup KD, (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29: 57-61.
4. Ricart AD, (2011) Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther 89: 513-523.
5. Goldenberg DM, Chang CH, Rossi EA, J W, McBride, et al, (2012) Pretargeted molecular imaging and radioimmunotherapy. Theranostics 2: 523-540.
6. Goldenberg DM, Chatal JF, Barbet J, Boerman O, Sharkey RM, (2007) Cancer Imaging and Therapy with Bispecific Antibody Pretargeting. Update Cancer Ther 2: 19-31.
7. Bagshawe KD, (1990) Antibody-directed enzyme/prodrug therapy (ADEPT). Biochem Soc Trans 18: 750-752.
8. Butlin NG, Meares CF, (2006) Antibodies with infinite affinity: origins and applications. Acc Chem Res 39: 780-787.
9. Meares CF, (2008) The chemistry of irreversible capture. Adv Drug Deliv Rev 60: 1383-1388.
10. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
11. Wu AM, (2004) Engineering multivalent antibody fragments for in vivo targeting. Methods Mol Biol 248: 209-225.
12. Milenic DE, Brady ED, Brechbiel MW, (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 3: 488-499.
13. Teicher BA, Chari RV, (2011) Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res 17: 6389-6397.
14. Fani M, Maecke HR, Okarvi SM, (2012) Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2: 481-501.
15. Fani M, Maecke HR, (2012) Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging 39Suppl 1: S11-30.
16. Reubi JC, Maecke HR, (2008) Peptide-based probes for cancer imaging. J Nucl Med 49: 1735-1738.
17. Liu Z, Niu G, Shi J, Liu S, Wang F, et al. (2009) (68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging. Eur J Nucl Med Mol Imaging 36: 947-957.
18. Ye Y, Bloch S, Xu B, Achilefu S, (2006) Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumors. J Med Chem 49: 2268-2275.
19. Garanger E, Boturyn D, Jin Z, Dumy P, Favrot MC, et al. (2005) New Multifunctional Molecular Conjugate Vector for Targeting, Imaging, and Therapy of Tumors. Mol Ther 16: 1168-1175.
20. Mittra ES, Goris ML, Iagaru AH, Kardan A, Burton L, et al. (2011) Pilot pharmacokinetic and dosimetric studies of (18)F-FPPRGD2: a PET radiopharmaceutical agent for imaging alpha(v)beta(3) integrin levels. Radiology 260: 182-191.
21. Beer AJ, Schwaiger M, (2011) PET imaging of alphavbeta3 expression in cancer patients. Methods Mol Biol 680: 183-200.
22. Dapp S, Garcia Garayoa E, Maes V, Brans L, Tourwe DA, et al. (2011) PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties. Nucl Med Biol 38: 997-1009.
23. Lohof E, Planker E, Mang C, Burkhart F, Dechantsreiter MA, et al. (2000) Carbohydrate Derivatives for Use in Drug Design: Cyclic alpha(v)-Selective RGD Peptides Angew Chem Int Ed Engl. 39: 2761-2764.
24. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G, (2006) Dosimetry in Peptide radionuclide receptor therapy: a review. J Nucl Med 47: 1467-1475.
25. Olafsen T, Wu AM, (2010) Antibody vectors for imaging. Semin Nucl Med 40: 167-181.
26. Fee CJ, Van Alstine JM, (2011) Purification of pegylated proteins. Methods Biochem Anal 54: 339-362.
27. Montet X, Montet-Abou K, Reynolds F, Weissleder R, Josephson L, (2006) Nanoparticle imaging of integrins on tumor cells. Neoplasia 8: 214-222.
28. Montet X, Funovics M, Montet-Abou K, Weissleder R, Josephson L, (2006) Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem 49: 6087-6093.
29. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, et al. (2005) MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J 19: 2008-2010.
30. Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Asgeirsdottir SA, et al. (2002) Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjug Chem 13: 128-135.
31. Dubey PK, Mishra V, Jain S, Mahor S, Vyas SP, (2004) Liposomes modified with cyclic RGD peptide for tumor targeting. J Drug Target 12: 257-264.
32. Porter CJ, Edwards GA, Charman SA, (2001) Lymphatic transport of proteins after s.c. injection: implications of animal model selection. Adv Drug Deliv Rev 50: 157-171.
33. Shore N, (2010) NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 19: 305-310.
34. Naspro R, Salonia A, Colombo R, Cestari A, Guazzoni G, et al. (2005) Update of the minimally invasive therapies for benign prostatic hyperplasia. Curr Opin Urol 15: 49-53.
35. Dmochowski R, Appell RA, (2003) Advancements in minimally invasive treatments for female stress urinary incontinence: radiofrequency and bulking agents. Curr Urol Rep 4: 350-355.
36. Benshushan A, Brzezinski A, Shoshani O, Rojansky N, (1998) Periurethral injection for the treatment of urinary incontinence. Obstet Gynecol Surv 53: 383-388.
37. Sherman W, Martens TP, Viles-Gonzalez JF, Siminiak T, (2006) Catheter-based delivery of cells to the heart. Nat Clin Pract Cardiovasc Med 3Suppl 1: S57-64.
38. Montet X, Yuan H, Weissleder R, Josephson L, (2006) Enzyme-based visualization of receptor-ligand binding in tissues. Lab Invest 86: 517-525.
39. Velikyan I, Xu H, Nair M, Hall H, (2012) Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE. Nucl Med Biol 39: 628-639.
40. Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, et al. (2010) Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 37: 1335-1344.
41. Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, et al. (2011) Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res 71: 1009-1018.
42. Forrer F, Uusijarvi H, Storch D, Maecke HR, Mueller-Brand J, (2005) Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 46: 1310-1316.
43. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, et al. (2012) Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging 39Suppl 1: S103-112.
44. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, et al. (2002) Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8: 1781-1807.
45. Villard L, Romer A, Marincek N, Brunner P, Koller MT, et al. (2012) Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers. J Clin Oncol 30: 1100-1106.
46. Antczak C, Jaggi JS, LeFave CV, Curcio MJ, McDevitt MR, et al. (2006) Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug Chem 17: 1551-1560.
47. McDevitt MR, Ma D, Simon J, Frank RK, Scheinberg DA, (2002) Design and synthesis of 225Ac radioimmunopharmaceuticals. Appl Radiat Isot 57: 841-847.
48. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T, Tennvall J, (2003) Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66: 107-117.
49. Shao F, Yuan H, Josephson L, Weissleder R, Hilderbrand SA, (2011) Facile Synthesis of Monofunctional Pentamethine Carbocyanine Fluorophores. Dyes Pigm 90: 119-122.
50. Garanger E, Aikawa E, Reynolds F, Weissleder R, Josephson L (2008) Simplified syntheses of complex multifunctional nanomaterials. Chem Commun (Camb): 4792-4794.
51. Garanger E, Blois J, Hilderbrand SA, Shao F, Josephson L, (2010) Divergent oriented synthesis for the design of reagents for protein conjugation. J Comb Chem 12: 57-64.
52. Kuil J, Buckle T, Yuan H, van den Berg NS, Oishi S, et al. (2011) Synthesis and evaluation of a bimodal CXCR4 antagonistic Peptide. Bioconjug Chem 22: 859-864.